Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of Lomedeucitinib (BMS-986322) in Healthy Participants
NCT04175925Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lomedeucitinib in plaque psoriasis (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Death up to 12 months, Incidence of Adverse Effects (AEs) up to 12 months and 9 more. Started Nov 2019; status: completed.
02
Drugs
lomedeucitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04175925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04175925.